Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.
about
Structural Evidence for Effectiveness of Darunavir and Two Related Antiviral Inhibitors against HIV-2 ProteaseFrequency of human immunodeficiency virus type-2 in hiv infected patients in Maputo City, MozambiqueTransmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg databaseImproving HIV-2 detection by a combination of serological and nucleic acid amplification test assays.HIV type 2 protease, reverse transcriptase, and envelope viral variation in the PBMC and genital tract of ARV-naive women in SenegalPolymorphisms of HIV-2 integrase and selection of resistance to raltegravirRevealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsCell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patientsG140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.A modular system to evaluate the efficacy of protease inhibitors against HIV-2Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitorsThe Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West AfricaComplex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.Antiretroviral drug resistance in human immunodeficiency virus type 2.Clinical evaluation of BioPlex 2200 HIV Ag-Ab, an automated screening method providing discrete detection of HIV-1 p24 antigen, HIV-1 antibody, and HIV-2 antibody.Performance of rapid tests for discrimination between HIV-1 and/or HIV-2 infections.HIV-2 Protease resistance defined in yeast cells.Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
P2860
Q27652399-EA4A6DDC-52A2-4BBB-9E2D-300BE14E261FQ30406079-8D0FC463-EA75-4DA9-988C-0243D01F78EAQ33321434-57F03944-75EF-44F3-AE15-366E20692F0CQ34046466-C245C9DB-3E60-45D5-BB6D-C12D59116A9DQ34080828-BF3B5707-E7C9-4C7E-85F7-377E9DF7175BQ34426605-611E9994-3894-479C-8E88-5166714C9168Q34440391-4769F279-D6D5-47AB-B9EA-E43A7D300FA0Q34730950-A569EA44-35C9-4557-BC96-FE7553E6648EQ34742090-7AEC22C6-F5AE-4CC5-B9D8-84437DE543D8Q35206272-57798F7F-08EF-4D64-B7B7-06E55F610B72Q35445731-C10C4B68-198F-47E6-907B-AC0B342B145DQ35636029-417E19F5-6908-4B0C-B960-2803D2F4F6B5Q36290647-057E69C3-028E-490D-8C3F-893B3C2E0999Q36538702-9305809D-061C-466C-8842-88C85034A79CQ36897863-BBA3516E-91F9-4630-B319-94035401AD8AQ37026564-12F9E548-5E8B-4E1B-97FE-7EC8DE468B0AQ37083896-874FBFF3-B2C2-4E2D-9BBC-647B90AD661DQ37256366-541E18FE-2916-4A54-9B89-774B822BC325Q37496287-A2322BA2-A1C7-4763-8EA7-078429865012Q37546640-19E59173-51A7-4794-B119-863D8C2F255BQ41156500-82F3A773-AA0C-486C-8BE7-0F0D1CFF16EAQ43249256-95BDE630-BF59-404E-9054-57E9847051C3Q46933139-F036F7D2-3026-4084-A865-54B6ABB11DF4
P2860
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Polymorphism of the human immu ...... ated with protease inhibitors.
@ast
Polymorphism of the human immu ...... ated with protease inhibitors.
@en
type
label
Polymorphism of the human immu ...... ated with protease inhibitors.
@ast
Polymorphism of the human immu ...... ated with protease inhibitors.
@en
prefLabel
Polymorphism of the human immu ...... ated with protease inhibitors.
@ast
Polymorphism of the human immu ...... ated with protease inhibitors.
@en
P2093
P2860
P1476
Polymorphism of the human immu ...... ated with protease inhibitors.
@en
P2093
Brun-Vezinet F
Descamps D
Peytavin G
P2860
P304
P356
10.1128/JCM.43.1.484-487.2005
P407
P577
2005-01-01T00:00:00Z